Terms: = Kidney tumors AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
160 results:
1. Association between pd-l1 Expression and the prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma.
Chrabańska M; Szweda-Gandor N; Rynkiewicz M; Hraboš D; Drozdzowska B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612724
[TBL] [Abstract] [Full Text] [Related]
2. GHITM regulates malignant phenotype and sensitivity to PD-1 blockade of renal cancer cells via Notch signalling.
Huang S; Liu J; Hu J; Hou Y; Hu M; Zhang B; Luo H; Fu S; Chen Y; Liu X; Chen Z; Wang L
J Cell Mol Med; 2024 Apr; 28(8):e18290. PubMed ID: 38588015
[TBL] [Abstract] [Full Text] [Related]
3. Association of Androgen Receptor and pd-l1 Expression in Upper Urinary Tract Urothelial Carcinoma.
Okuda Y; Kato T; Fujita K; Fushimi H; Miyamoto H; Netto GJ; Nonomura N
Cancer Genomics Proteomics; 2024; 21(2):137-143. PubMed ID: 38423597
[TBL] [Abstract] [Full Text] [Related]
4. N
Li C; Zhu M; Gao C; Lu F; Chen H; Liu J; Zhong W
Front Biosci (Landmark Ed); 2024 Jan; 29(1):33. PubMed ID: 38287827
[TBL] [Abstract] [Full Text] [Related]
5. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
6. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
Meng L; Collier KA; Wang P; Li Z; Monk P; Mortazavi A; Hu Z; Spakowicz D; Zheng L; Yang Y
Cells; 2023 Dec; 13(1):. PubMed ID: 38201238
[TBL] [Abstract] [Full Text] [Related]
7. Understanding Factors that Influence prognosis and Response to Therapy in Clear Cell Renal Cell Carcinoma.
Jia L; Cowell LG; Kapur P
Adv Anat Pathol; 2024 Mar; 31(2):96-104. PubMed ID: 38179997
[TBL] [Abstract] [Full Text] [Related]
8. [Clinicopathological features of intravascular large B-cell lymphoma and collision tumors of five cases].
Liu J; Liu GZ; Xia L; Wang HY; Zhang XF; Liu H
Zhonghua Bing Li Xue Za Zhi; 2024 Jan; 53(1):22-28. PubMed ID: 38178742
[No Abstract] [Full Text] [Related]
9. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
[TBL] [Abstract] [Full Text] [Related]
10. SCGN and STAT3 expressions are associated with the prognosis of ccRCC.
Lai C; Gong J; Tang J; Liu Q; Zhang M; Lai M; Zhang D; Teng X
Pathol Res Pract; 2023 Dec; 252():154940. PubMed ID: 37977033
[TBL] [Abstract] [Full Text] [Related]
11. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
[TBL] [Abstract] [Full Text] [Related]
12. Inflammatory response-based prognostication and personalized therapy decisions in clear cell renal cell cancer to aid precision oncology.
Zhong W; Chen H; Yang J; Huang C; Lin Y; Huang J
BMC Med Genomics; 2023 Oct; 16(1):265. PubMed ID: 37885006
[TBL] [Abstract] [Full Text] [Related]
13. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
[TBL] [Abstract] [Full Text] [Related]
14. Establishment of a Seven-Gene Signature Associated with CD8
Chen Y; Zhou X; Xie Y; Wu J; Li T; Yu T; Pang Y; Du W
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762031
[TBL] [Abstract] [Full Text] [Related]
15. Acute kidney injury in patients with cancer receiving anti-PD-1/pd-l1 antibodies: incidence, risk factors, and prognosis.
Lou Q; Gong J; Ye B; Yu R; Bu S; Li Y; Zhu B; Shao L
Ren Fail; 2023 Dec; 45(1):2238823. PubMed ID: 37491871
[TBL] [Abstract] [Full Text] [Related]
16. Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity.
Wu Y; Lin Z; Tang X; Tong Z; Ji Y; Xu Y; Zhou Z; Yang J; Li Z; Liu T
Front Immunol; 2023; 14():1182030. PubMed ID: 37388742
[TBL] [Abstract] [Full Text] [Related]
17. The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma.
Su J; Zhou L; Zhang Z; Xiao X; Qin Y; Zhou X; Huang T
Front Immunol; 2023; 14():1146738. PubMed ID: 37350955
[TBL] [Abstract] [Full Text] [Related]
18. The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature.
Ventriglia J; Passarelli A; Pisano C; Cecere SC; Rossetti S; Feroce F; Forte M; Casartelli C; Tambaro R; Pignata S; Perversi F; Di Napoli M
Crit Rev Oncol Hematol; 2023 Aug; 188():104036. PubMed ID: 37263397
[TBL] [Abstract] [Full Text] [Related]
19. Effect of cd274 (pd-l1) overexpression on survival outcomes in 10 specific cancers: a systematic review and meta-analysis.
Park JH; Luchini C; Nottegar A; Tizaoui K; Koyanagi A; Ogino S; Shin JI; Lim BJ; Smith L
J Clin Pathol; 2023 Jul; 76(7):450-456. PubMed ID: 37130750
[TBL] [Abstract] [Full Text] [Related]
20. SAA1 Has Potential as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, and an Indicator for Immune Infiltration of Tumor Microenvironment in Clear Cell Renal Cell Carcinoma.
Xu Z; Wu Y; Fu G; Chen X; Sun J; Tian J; Jiang P; Wang Y; Jin B
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108666
[TBL] [Abstract] [Full Text] [Related]
[Next]
